RCM Technologies, Inc.

RCM Technologies, Inc. (RCMT) Market Cap

RCM Technologies, Inc. has a market capitalization of $169.3M.

Price: $23.89

0.11 (0.46%)

Market Cap: 169.32M

NASDAQ · time unavailable

CEO: Bradley S. Vizi

Sector: Industrials

Industry: Conglomerates

IPO Date: 1983-09-12

Website: https://www.rcmt.com

RCM Technologies, Inc. (RCMT) - Company Information

Market Cap: 169.32M|Sector: Industrials

Company Profile

RCM Technologies, Inc. provides business and technology solutions in the United States, Canada, Puerto Rico, and Serbia. It operates through three segments: Engineering, Specialty Health Care, and Life Sciences and Information Technology. The Engineering segment offers a range of engineering services, including project management engineering and design, engineering analysis, engineer-procure-construct, configuration management, hardware/software validation and verification, quality assurance, technical writing and publications, manufacturing process planning and improvement, and 3D/BIM integrated design. The Specialty Health Care segment provides long-term and short-term staffing, executive search, and placement services in the fields of allied and therapy staffing, correctional healthcare staffing, health information management, nursing services, physician and advanced practice, school services, and telepractice. The Life Sciences and Information Technology segment provides enterprise business solutions, application services, infrastructure solutions, competitive advantage, life sciences solutions, and other vertical market specific solutions. The company serves aerospace and defense, energy, financial services, health care, life sciences, manufacturing and distribution, and technology industries, as well as educational institutions and the public sector. RCM Technologies, Inc. was founded in 1971 and is based in Pennsauken, New Jersey.

Analyst Sentiment

83%
Strong Buy

From 2 Active Polls

Consensus Target Matrix

Data feed parsing pending...

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$25.08
▲ +5.00% Upside
Low Target
$17.92
-25% Risk
Median Target
$24.37
2% Mid
High Target
$29.86
25% Max
Consensus
Buy
2 / 3 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MApr 4, 2026Jan 3, 2026Sep 27, 2025Jun 28, 2025Mar 29, 2025Dec 28, 2024Sep 28, 2024Jun 29, 2024
Market Cap ($M)169147151206176121176159146
Enterprise Value ($M)201179174242211146214194172
Price to Earnings Ratio (P/E)11.389.566.1922.7611.637.2115.3614.459.69
Price/Earnings-to-Growth Ratio (PEG)0.270.73
Price to Sales Ratio (P/S)0.531.771.752.932.251.432.292.632.11
Price to Book Ratio (P/B)4.113.323.294.974.663.495.265.285.12
Price to Free Cash Flow Ratio (P/FCF)45.6457.1213.44-116.86-21.087.44-67.23-32.6127.37
Enterprise Value to Sales (EV/Sales)2.152.013.452.701.732.783.212.49
Enterprise Value to EBITDA (EV/EBITDA)7.4927.5519.5754.1130.1620.8528.9141.6127.72
Debt to Equity Ratio1.190.780.560.921.070.881.261.261.04

RCMT Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$23.89
Intrinsic Value$23.86
Market Alignment
Overvalued by 0.1%relative to calculated intrinsic value
9.00%
Exp: 13%13%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.04B
Perpetuity TV Value$0.84B
Discounted TV (PV)$0.35B
TV Weighting %64.0%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 RCM TECHNOLOGIES INC (RCMT) — Investment Overview

🧩 Business Model Overview

RCM Technologies Inc operates in the healthcare revenue cycle management (RCM) ecosystem, helping providers capture, bill, and collect reimbursements with a blend of technology enablement and operational services. The value chain typically spans patient access workflows (eligibility and prior authorization support), clinical documentation/coding enablement, claim submission and adjudication follow-up, and denial management. In practice, RCMT’s output is “financial outcomes” for providers—improved claim accuracy, faster reimbursement cycles, and reduced leakage—delivered through workflows that must fit into each customer’s existing billing stack and EHR-related data flows.

This fit-to-workflow requirement creates practical stickiness: process changes, integration work, and training are hard to unwind, particularly when teams rely on day-to-day operational expertise and standardized performance reporting.

💰 Revenue Streams & Monetisation Model

Revenue is generally monetized through a mix of (1) contract-based managed service fees (often structured per client account scope), (2) transaction- or outcome-linked fees tied to claim handling/capture and resolution activities, and (3) technology-enabled implementation or support services where applicable. The monetisation model tends to be partially recurring because RCM operations are ongoing processes rather than one-time projects.

Margin drivers include operational efficiency (labor productivity, standardization of coding/denial workflows), automation of rules-based steps, and scalable delivery across customer accounts. When RCMT can compress cycle times and improve claim acceptance rates without proportionate cost increases, contribution margins benefit—especially when the company’s process knowledge reduces rework and denial volumes.

🧠 Competitive Advantages & Market Positioning

Primary moat: High switching costs (workflow/data integration + operational know-how). RCM is not plug-and-play. Providers and their revenue teams depend on tight integration with billing systems, claims processes, and documentation conventions. Replacing an RCM vendor requires rebuilding interfaces, revalidating claim logic, retuning denial/appeal playbooks, and re-training staff—creating meaningful switching friction.

Secondary moat: Intangible assets in compliance and payer-facing execution. Healthcare reimbursement is rule-dense and changes with policy and billing standards. Competitive advantage often reflects execution quality: coding/charge capture discipline, claims handling accuracy, and a documented approach to denial and appeal management that reduces avoidable leakage.

  • Competitor 1: R1 RCM — a large-scale RCM services provider with broader outsourcing footprints. RCMT’s competitive focus is more provider-services/technology-enabled execution within the RCM value chain rather than pure scale arbitrage.
  • Competitor 2: Change Healthcare (part of Optum / UnitedHealth ecosystem) — emphasizes technology, connectivity, and revenue integrity tooling. RCMT differentiates through operational delivery and workflow fit rather than relying primarily on platform distribution.
  • Competitor 3: Conifer Health (provider of RCM/BPO services; integrated within UnitedHealth Group) — competes on managed services for billing and denial workflows. RCMT’s positioning centers on specific RCM execution capabilities that reduce leakage and improve cash collection for target provider segments.

Overall, RCMT’s industry positioning benefits from a “stickiness” dynamic: customers are incentivized to retain a vendor that understands their operational specifics and delivers measurable financial outcomes, reducing the probability of churn even when procurement cycles remain competitive.

🚀 Multi-Year Growth Drivers

  • Ongoing pressure to improve provider cash flow and reimbursement reliability. As reimbursement rules evolve and administrative complexity persists, demand for RCM capabilities remains structurally supported.
  • Denial and revenue leakage management remains a persistent cost center. Providers seek systematic reduction in claim denials, underpayments, and rework—supporting continued outsourcing/augmentation of RCM functions.
  • Automation + workflow digitization increases the value of process-rich operators. AI and automation can reduce manual effort, but high-quality outcomes still require domain expertise to configure rules, monitor accuracy, and manage edge cases. Vendors with deep operational playbooks can capture more value from digitization than purely transactional competitors.
  • TAM expansion through provider network complexity. Multi-site operations, payer diversity, and documentation variability drive ongoing needs for specialized RCM execution and integration.

⚠ Risk Factors to Monitor

  • Regulatory and reimbursement policy shifts. Changes in billing standards, documentation expectations, or reimbursement rules can reduce the effectiveness of playbooks and require rapid operational adjustment.
  • Technology disruption and competitive pricing. Automation lowers the cost of some RCM steps, increasing competitive intensity and potentially compressing margins if vendors compete primarily on price.
  • Cybersecurity and protected health information (PHI) exposure. RCM processes involve sensitive data and payer communications, creating material operational and reputational risk from breaches.
  • Customer concentration and contract renewal dynamics. Provider budgets and contracting behavior can shift, impacting retention and growth.
  • Operational execution risk. Sustained performance depends on staffing quality, training, and process discipline; deficiencies can increase denial rates and erode customer trust.

📊 Valuation & Market View

Healthcare IT and RCM services are often valued using EV/EBITDA and P/S frameworks, reflecting the market’s focus on durable cash generation, contract-based revenue characteristics, and operating margin potential. Valuation sensitivity typically tracks:

  • Revenue durability and contract retention (evidence of switching cost/embedded relationships).
  • Unit economics and operating leverage (labor productivity, reduced rework/denials, scalable delivery).
  • Quality and compliance performance (audit outcomes, accuracy metrics, and customer satisfaction/renewal signals).
  • Cyber and regulatory risk profile (risk-adjusted confidence in long-term execution).

In this sector, investors generally pay for a combination of growth visibility and margin durability rather than purely top-line expansion.

🔍 Investment Takeaway

RCM Technologies Inc fits a durable healthcare services profile where high switching costs and process- and compliance-driven intangible assets help sustain customer relationships in an RCM environment characterized by persistent reimbursement complexity. The long-term thesis rests on continued demand for denial and leakage reduction, the ability to extract operating leverage through workflow automation, and maintenance of execution quality amid regulatory change—while managing cyber and competitive pricing risk.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for RCMT.

zacks.com2026-06-03

Is Trending Stock RCM Technologies, Inc. (RCMT) a Buy Now?

RCM Technologies (RCMT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

zacks.com2026-05-25

Is RCM Technologies (RCMT) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

newsfilecorp.com2026-05-20

Everyday People Financial Corp. Reports Q1 2026 Revenue Growth of 35% to $20.4 Million from $15.1 Million from Continuing Operations; AI-Enhanced RCM Platform Scales Operations, Adding 116 Fee-Earning Employees to Support Organic Client Growth While Driving Productivity Improvements

Edmonton, Alberta--(Newsfile Corp. - May 20, 2026) - Everyday People Financial Corp. (TSXV: EPF) (OTCQB: EPFCF) ("EP Financial" or the "Company") today reported financial results for the three months ended March 31, 2026. Total revenue from continuing operations increased 35% to $20.4 million, compared to $15.1 million in the same period of 2025, reflecting the continued scaling of the Company's receivables management business.

zacks.com2026-05-20

RCM Technologies, Inc. (RCMT) is Attracting Investor Attention: Here is What You Should Know

RCM Technologies (RCMT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

zacks.com2026-05-19

Is RCM Technologies (RCMT) Outperforming Other Business Services Stocks This Year?

Here is how RCM Technologies, Inc. (RCMT) and Ralliant (RAL) have performed compared to their sector so far this year.

zacks.com2026-05-07

Should Value Investors Buy RCM Technologies (RCMT) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com2026-05-01

RCM Technologies (RCMT) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, RCM Technologies (RCMT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

defenseworld.net2026-04-27

RCM Technologies (NASDAQ:RCMT) CFO Sells $93,941.28 in Stock

RCM Technologies, Inc. (NASDAQ: RCMT - Get Free Report) CFO Kevin Miller sold 2,932 shares of the stock in a transaction on Friday, April 24th. The shares were sold at an average price of $32.04, for a total value of $93,941.28. Following the completion of the sale, the chief financial officer directly owned 443,800 shares of

zacks.com2026-04-24

RCM Technologies, Inc. (RCMT) Outpaces Stock Market Gains: What You Should Know

The latest trading day saw RCM Technologies, Inc. (RCMT) settling at $31.62, representing a +2.26% change from its previous close.

zacks.com2026-04-24

Is RCM Technologies (RCMT) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

zacks.com2026-04-22

Why RCM Technologies, Inc. (RCMT) Outpaced the Stock Market Today

In the closing of the recent trading day, RCM Technologies, Inc. (RCMT) stood at $31.62, denoting a +1.77% move from the preceding trading day.

newsfilecorp.com2026-04-22

Everyday People Financial Corp. Reports 33% Revenue Growth to $76.2 Million for Fiscal 2025, Driven by 47% Growth in RCM Revenue to $69.7 Million; RCM Adjusted EBITDA of $9.4 Million and Total Adjusted EBITDA of $8.0 Million, Up 116%

Edmonton, Alberta--(Newsfile Corp. - April 22, 2026) - Everyday People Financial Corp. (TSXV: EPF) (OTCQB: EPFCF) ("EP Financial" or the "Company") today reported financial results for the year ended December 31, 2025. Total consolidated revenue increased 33% to $76.2 million, compared to $57.1 million in 2024.

zacks.com2026-04-22

Top Stocks From the Staffing Services Industry to Buy Now

RCMT, HQI and PEGA highlight top staffing stocks as AI-driven HR platforms, flexible hiring and workforce solutions fuel investor interest.

zacks.com2026-04-16

RCM Technologies, Inc. (RCMT) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, RCM Technologies, Inc. (RCMT) closed at $30.36, indicating a +1.5% shift from the previous trading day.

zacks.com2026-04-16

5 Stocks With Recent Price Strength to Maximize Your Returns

IDN, CDNL, RCMT, AUGO and MG surge on strong momentum, with sharp price gains and rising earnings estimates signaling potential for continued upside.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-04-04

"RCMT reported Q1 2026 revenue of $83.0M and net income of $3.84M (EPS $0.50). On a YoY basis (vs Q1 2025), revenue declined to $83.0M from $84.5M (-1.5%) while net income improved to $3.84M from $4.19M (-8.2%). QoQ (vs Q4 2025) revenue decreased to $83.0M from $86.5M (-4.1%), and net income fell to $3.84M from $6.10M (-37.0%). Profitability weakened: gross margin eased to 26.5% from 27.4% QoQ, and net margin contracted to 4.63% from 7.06% QoQ. Cash flow quality appears mixed. Operating cash flow was $2.67M in Q1 2026 versus $11.45M in Q4 2025, yielding free cash flow of $2.67M (no capex). Balance sheet leverage is much lighter than prior periods: total assets were $135.3M and equity was $44.3M; total debt fell materially to $4.75M, with net debt about $2.13M. Total shareholder returns are strong given the stock’s momentum (1Y change +96.3%) and no dividend activity indicated. Analyst valuation data is incomplete (no price targets), but the recent price run suggests expectations for operating durability despite near-term earnings volatility."

Revenue Growth

Neutral

QoQ revenue fell from $86.5M to $83.0M (-4.1%); YoY revenue slightly down from $84.5M to $83.0M (-1.5%), indicating modest top-line softness.

Profitability

Caution

Net margin contracted to 4.63% in Q1 2026 from 7.06% QoQ; net income declined QoQ (-37.0%). YoY net income was lower (-8.2%), showing profitability pressure.

Cash Flow Quality

Neutral

Operating cash flow dropped to $2.67M from $11.45M QoQ. However, with minimal/no capex in the quarter, free cash flow matched OCF ($2.67M). No dividends were paid; buybacks were not reported this quarter.

Leverage & Balance Sheet

Strong

Balance sheet resilience improved sharply: total assets rose slightly to $135.3M, equity increased to $44.3M, and total debt decreased to $4.75M with net debt ~ $2.13M.

Shareholder Returns

Strong

High price momentum: 1Y change +96.3% meaning capital appreciation is the dominant component. Dividend yield is shown as 0 and no buyback activity is indicated in Q1.

Analyst Sentiment & Valuation

Neutral

Price targets were not provided (priceTarget: null), limiting confidence in valuation upside/downside. Prior-quarter valuation ratios suggest the market previously priced earnings growth aggressively.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Management presented Q4 and 2026 as stronger (record 2026 engineering backlog; expected highest Q4 gross profit and adjusted EBITDA), and the tone is confident on growth drivers: healthcare penetration, Energy Services execution, and Life Sciences AI/compliance initiatives. However, the Q&A reveals near-term operational pressure points. Cash flow was “disappointing” in Q3 due to administrative collection issues with two large school clients. Healthcare is also carrying a heavy medical-claims overhang—$0.8M over budget in Q3 and $1.8M year-to-date—described as hard to forecast and driven by inflationary hospital/insurance cost pressures. Seasonal forecasting also missed on summer-session demand. Foreign nurse hiring is promising (300+ passed exams; potential 50–60 added if visa dates shift by a few months), but timing is explicitly dependent on visa retrogression—analysts pressed for order-of-magnitude impact and got uncertainty. Energy Services is confident but “don’t get too far over your skis” signals discipline amid active market opportunities.

AI IconGrowth Catalysts

  • Record 2026 engineering backlog (end of October) and increased traction with existing healthcare clients
  • Energy Services: record backlog for 2026 and momentum in integrated engineering + EPC for grid hardening/modernization
  • Aerospace & Defense: momentum in existing programs and awards such as Bell Flight Best New Supplier (2025)
  • Life Sciences: AI-driven computer software validation/equipment qualification partnership to streamline compliance and reduce turnaround times
  • Healthcare: increased penetration with existing K-12 school clients and pipeline for 300+ foreign-trained nurses ready to deploy pending visa timing

Business Development

  • Healthcare: expanding roster of new school partners and broadened commitments from existing school clients (K-12 staffing)
  • Life Sciences: partnering with an AI-driven computer software validation and equipment qualification company (named not provided)
  • Energy Services: deepening strategic partnerships with OEMs to improve procurement agility and mitigate equipment lead time constraints
  • Aerospace & Defense: Bell Flight recognized RCMT as Best New Supplier in 2025

AI IconFinancial Highlights

  • Q3 consolidated gross profit: $19.4M (+8.8% YoY)
  • Q3 adjusted EBITDA: $5.5M vs $5.6M prior year (down 1.4%)
  • Q3 adjusted EPS: $0.42 (flat vs Q3 2024)
  • Healthcare Q3 gross profit: $9.0M vs $8.3M (+8.5%) but gross margin down to 30.0% vs 31.2%
  • Healthcare Q3 revenue: school revenue $24.4M vs $20.2M (+20.7%); non-school revenue $5.6M vs $6.4M (-11.3%)
  • Engineering Q3 gross profit: $6.9M vs $5.9M (+17.3%) but gross margin down to 22.0% vs 24.4%
  • IT/Life Sciences/Data Solutions Q3 gross profit: $3.5M vs $3.7M (-4.2%); gross margin up to 39.5% vs 38.0%
  • Medical claims headwind: SG&A included $0.8M costs over budget in Q3 alone and $1.8M year-to-date
  • Cash flow: CFO said they were disappointed with Q3 cash flow from operations due to administrative collection issues with 2 large school clients
  • Guidance tone: management expects Q4 to deliver highest quarterly gross profit and highest adjusted EBITDA in fiscal 2025

AI IconCapital Funding

  • No explicit buyback dollar amount stated in this transcript
  • Revolver in place; management states it provides ample capacity/financial flexibility
  • Capital allocation context: management referenced prior share repurchases totaling 45% of outstanding shares (current outstanding ~7.4M shares) and average cost ~ $8.50 per share; ability to delever quickly

AI IconStrategy & Ops

  • Healthcare seasonality issue in Q3: softer June/July/August due to fewer students in summer session and unpredictability year-to-year; Q3 recovered in September
  • Medical cost mitigation: long-term measures to reduce medical claims costs; also discussed self-insured strategy
  • Self-insured vs fully insured: company is self-insured (800+ covered lives); management said switching fully insured would be worse at their size
  • Energy Services execution: hybrid resourcing model (domestic + global engineering design centers) and use of 3D BIM/digitalization
  • Engineering mix/gross margin explanation: gross margin variability driven by revenue mix and amount of work performed by subs vs salaried employees; Aerospace lower margin; Industrial Processing randomness due to fixed direct-cost base
  • Life Sciences operating emphasis: dedicated life sciences engineering group and integration of AI-driven compliance; scaling managed service offering

AI IconMarket Outlook

  • Energy Services backlog: Q3 update stated 2026 backlog just over $70M vs $21M backlog for 2025 at the same time last year
  • Q4 expectations: highest quarterly gross profit and highest adjusted EBITDA in fiscal 2025
  • Foreign nurse pipeline timing: CFO expects visa retrogression dates could move in Q4; even with a 3–4 month shift, could bring over 50–60 nurses; 300+ nurses already passed exams and are in the pipeline

AI IconRisks & Headwinds

  • Healthcare medical costs: excess medical costs ~ $1.8M year-to-date with Q3 particularly hard; insurance premiums up significantly in 2025 vs 2024; medical claims difficult to forecast
  • Cash flow risk: administrative collection issues with 2 large school clients caused disappointing operating cash flow in Q3
  • Foreign recruitment execution risk: impact depends on visa retrogression; timing uncertain (management could not predict timing reliably)
  • Healthcare seasonality/revenue risk: July/August revenue lower than expected due to fewer students taking summer session and less staffing need than forecast
  • Industrial Process unit underperformance risk: strategy/personnel changes underway; unit is stable and small and unlikely to move needle, but management acknowledged it 'needs to be on a different trajectory'
  • Engineering margins headwind: YoY gross margin down in engineering and Healthcare (mix effects and sub vs salaried work; Aerospace/Industrial Processing randomness)

Sentiment: MIXED

Note: This summary was synthesized by AI from the RCMT Q3 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for RCMT.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (RCMT)

© 2026 Stock Market Info — RCM Technologies, Inc. (RCMT) Financial Profile